Effect of Evolocumab or Ezetimibe Added to Moderate- or High-Intensity Statin Therapy on LDL-C Lowering in Patients With Hypercholesterolemia: The LAPLACE-2 Randomized Clinical Trial

Overview of attention for article published in JAMA: Journal of the American Medical Association, May 2014

Altmetric Badge

About this Attention Score

In the top 5% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (99th percentile)
High Attention Score compared to outputs of the same age and source (87th percentile)

Mentioned by

news: 12 news outlets
blogs: 1 blog
policy: 1 policy source
twitter: 27 X users
patent: 4 patents

weibo: 2 weibo users
facebook: 3 Facebook pages
wikipedia: 2 Wikipedia pages
guideline: 4 clinical guideline sources

Readers on

mendeley: 464 Mendeley

So far, Altmetric has seen 28 X posts from 27 X users, with an upper bound of 527,257 followers.

@dmrind @DBelardoMD ApoB lowering reduces ASCVD events in ACS patients (PROVE-IT, ODYSSEY OUTCOMES, IMPROVE-IT) and stable CAD (4S, FOURIER, and REVEAL) EZE % lowering is similar w hi & mod-intensity statins. https://t.co/HhQSxwSqxV add’l links: http…

RT @GudeDiego: El siguiente paso a las estatinas: inhibidores de PCSK4 https://t.co/dKNIDODDtF Antecedente de evento coronario: más del 95%…

El siguiente paso a las estatinas: inhibidores de PCSK4 https://t.co/dKNIDODDtF Antecedente de evento coronario: más del 95% de los pacientes con evolocumab + estatina de alta intensidad mantiene LDL <70, frente al 60% de los pacientes tratados con ato…

RT @JAMA_current: #Evolocumab or #ezetimibe added to #statin therapy—the LAPLACE #RCT http://t.co/C0yiCGAByG http://t.co/tXMo9AlJWc

This page shows the most recent X posts that mention this research output. Click here to find out how to access more activity, including 24 additional X posts.